<DOC>
	<DOCNO>NCT02545114</DOCNO>
	<brief_summary>Hyponatremia occur frequently patient acute brain injury day week follow injury , may contribute adverse outcome . In addition , hyponatremia aggravate neurologic dysfunction , complicate neurological assessment , contribute neurologic symptom gait dysfunction impair effort mobilization rehabilitation . Strict normonatremia ( serum Na level 135 145 meq/dl ) goal patient acute brain injury . SIADH frequent cause hyponatremia patient neurological injury ; however , treatment fluid restriction often difficult contra-indicated , example patient subarachnoid hemorrhage ( SAH ) intravascular hypovolemia trigger vasospasms . The aim project test Tolvaptan , ADH antagonist , treatment select patient acute brain injury develop SIADH .</brief_summary>
	<brief_title>Tolvaptan Patients With Acute Neurological Injuries</brief_title>
	<detailed_description>Hyponatremia occur frequently patient acute brain injury day week follow acute injury , may contribute adverse outcome ( 1 ) . In addition , hyponatremia aggravate neurologic dysfunction , complicate neurological assessment , contribute neurologic symptom gait dysfunction impair effort mobilization rehabilitation . Strict normonatremia ( serum Na level 135 145 meq/dl ) goal patient acute brain injury . Various study show SIADH ( syndrome inappropriate anti-diuretic hormone secretion ) far frequent cause hyponatremia patient acute neurological injury ( 1-4 ) . However , frequently recommend standard therapy SIADH fluid restriction often impractical , counter-indicated impossible implement neurocritical patient . For example , patient admit subarachnoid hemorrhage ( SAH ) require maintenance euvolemic state prevent vasospasms ; often , high volume fluid require prevent even brief episode hypovolemia , may trigger vasospasms [ 5-8 ] . Thus many patient treat hypertonic saline , usually effective , price induce hypervolemia possible ( worsen ) cardiac dysfunction ( also occurs often patient acute brain injury , particular SAH ) . In addition , use hypertonic saline may require central venous access ICU monitoring , prevent transfer step-down unit otherwise stable patient . The investigator plan use Tolvaptan ( Samsca ) , oral ADH antagonist promotes aquauresis , agent treat neurologically hemodynamically stable patient acute neurological injury suspect SIADH . As drug currently approve 1-month use patient SIADH , patient acute brain injury develop transient SIADH duration day week , Tolvaptan would theory tailor-made population . However , experience Tolvaptan neurocritical patient limit . Current local hospital protocol call maintain normonatremia patient acute brain injury ( except patient brain edema treat hypertonic saline induce hypernatremia ) . Hyponatremia usually treat hypertonic saline time . The investigator aim use Tolvaptan patient admit neurological ICU develop SIADH , recurrence hyponatremia discontinuation hypertonic saline initially give correct hyponatremia , neurologically stable patient develop hyponatremia day ( one week ) admission . Tolvaptan give 3 day period , DC-ed restart immediately sodium level drop 135 meq . The maximum treatment duration 14 day . A key point attention patient receive sufficient fluid intake , either mouth able eat drink , via intravenous administration , combination . The minimum fluid intake must 2500 ml per 24 hour ; usually intake great , especially patient SAH . Thus fluid intake/fluid administration closely monitor . In practice , every patient continuous IV infusion 80-100 ml apart oral intake . Sodium level check every 4-6 hour , already standard practice patient acute brain injury develop hyponatremia . Primary endpoint : Normalization sodium level ( level 135-145 meq/dl ) . Secondary endpoint : 1. incidence vasospasms ; 2. incidence pulmonary edema ( defined evidence edema chest X ray ) ; 3. clinical outcome , include length stay ICU . Safety Liver enzymes monitor study patient autosomal dominant polycystic kidney disease , Tolvaptan use slow progression disease , report prolonged ( 3 month ) administration high dos ( 120 mg ) Tolvaptan link ( reversible ) rise OT PT , rare case bilirubin , patient ( 9 ) . However , previous study patient without polycystic kidney disease use Tolvaptan dose 60 mg one year report liver enzyme rise ( 10-11 ) . The high dose use 45 mg , maximum duration 2 week . Tolvaptan currently use occasionally daily clinical practice local neurological ICU 's . A review data 43 patient ( 34 SAH , 5 ICH , 2 AIS , 2 post-brain tumor surgery ) show drug successfully control hyponatremia patient use , without side effect note ( 12 ) . Average sodium level 129.4 meq treatment increase 135.8 meq within 48 hour . Median treatment duration 5 day ( average 4.3 day ) . No significant side effect note . Of note , liberal fluid intake ensure patient . Target patient population number . A total 80 patient acute neurological injury ; minimum 30 patient subarachnoid hemorrhage , 10 patient intracranial hemorrhage , 10 patient acute ischemic stroke , 10 patient traumatic brain injury , 10 patient undergone elective neurosurgical intervention . Inclusion criterion . - Patients euvolemic hypervolemic hyponatremia : serum Na &lt; 135 meq/dl - Inappropriately high urinary sodium excretion Exclusion criterion . - Clinically evident hypovolemic hyponatremia - Recent myocardial infarction cardiac surgery - Sustained ventricular tachycardia fibrillation - Systolic blood pressure le 90 mm Hg - Serum creatinine concentration 3 mg per deciliter - History , biochemical evidence , liver disease - Serum sodium concentration le 120 mmol per liter association neurologic impairment - Urinary tract obstruction - Use diuretic ( furosemide , burinex , hydrochlorthiazide ) safely discontinue - Concomitant use hypertonic saline ( prior use OK , hypertonic stop within 1 hour first dose Tolvaptan administration ) . - History chronic SIADH know chronic hyponatremia cause ( e.g . heart failure ) - Uncontrolled hypothyroidism adrenal insufficiency - Severe co-morbidities life expectancy &lt; 6 month - CMO status</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Trauma , Nervous System</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients euvolemic hypervolemic hyponatremia : serum Na &lt; 135 meq/dl Inappropriately high urinary sodium excretion Clinically evident hypovolemic hyponatremia Recent myocardial infarction cardiac surgery Sustained ventricular tachycardia fibrillation Systolic blood pressure le 90 mm Hg Serum creatinine concentration 3 mg per deciliter History , biochemical evidence , liver disease Serum sodium concentration le 120 mmol per liter association neurologic impairment Urinary tract obstruction Use diuretic ( furosemide , burinex , hydrochlorthiazide ) safely discontinue Concomitant use hypertonic saline ( prior use OK , hypertonic stop within 1 hour first dose Tolvaptan administration ) . History chronic SIADH know chronic hyponatremia cause ( e.g . heart failure ) Uncontrolled hypothyroidism adrenal insufficiency Severe comorbidities life expectancy &lt; 6 month CMO status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hyponatremia</keyword>
	<keyword>SIADH , stroke</keyword>
	<keyword>SAH ; ICH</keyword>
	<keyword>AIS</keyword>
</DOC>